Immunovant Inc annual revenue for fiscal TTM was $7 million, compared with $0 million in fiscal 2026. All figures are reported results from public filings — no estimates or projections.
| Revenue (annual) | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-12-31 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $7M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Revenue (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $7M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More IMVT metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All IMVT financial statements → Interactive IMVT charts →
About TickerBase · Data methodology & sources · Privacy · Terms